Article Figures & Data
Figures
- FIGURE 1.
Measured platelet counts (A) and ANCs (B) for patient 25 treated with 90Y-ibritumomab tiuxetan. All counts were normalized to baseline counts at beginning of radioimmunotherapy. PLT = platelet; RIT = radioimmunotherapy.
- FIGURE 2.
Linear regression of PBN on TLC for platelets (A) and neutrophils (B). (C and D) Results of linear regression of PBN on TLC performed separately for 90Y-ibritumomab tiuxetan and 131I-tositumomab groups. PLT = platelet.
- FIGURE 3.
Relationship between PBP and PBN for platelets (A) and neutrophils (B) in whole radioimmunotherapy patient population.
Tables
- TABLE 1
Fourteen Patient Characteristics (Variables) Considered as Potential Predictors of Hematologic Toxicity (32 Patients)
Variable Mean ± SD Range n Age at radioimmunotherapy (y) 63 ± 10 40–80 Number of prior chemotherapy regimens at radioimmunotherapy (including rituximab) 3.1 ± 1.7 1–8 Time since last chemotherapy (mo) 8.9 ± 6.4 1–26 Bone marrow dose (Gy) 1.6 ± 0.4* 1.0–2.0* 2.1 ± 0.4† 1.2–2.8† Baseline at time of radioimmunotherapy Platelets (103/mm3) 206 ± 100 67–535 Absolute neutrophil count (1/mm3) 3,860 ± 1,880 1,530–11,080 Male sex 23 (72%) Type of radioimmunotherapy agent 90Y-ibritumomab tiuxetan 14 (44%) 131I-tositumomab 18 (56%) Disease stage at radioimmunotherapy I–II 5 (16%) III–IV 27 (84%) Prior treatment with rituximab Alone 8 (25%) With chemotherapy 23 (72%) Refractory to rituximab 14 (44%) Bone marrow involvement at radioimmunotherapy 7 (22%) History of prior bone marrow transplant 4 (13%) History of prior radiation therapy 7 (22%) History of prior treatment with fludarabine 9 (28%) - TABLE 2
Patients Predicted with Thrombocytopenia Grade I or IV for Whom Dosing Regimens Were Reevaluated According to Toxicity-Prediction Model
Dosing regimen Patient no. Actual Proposed 2 H H+ 3* H L 6 H H+ 10 L L− 11 L L− 12 H H+ 15 L L− 18 H H+ 20 H L 21 H H+ 23 L L− 25* L H 28 L L− 29 L H ↵* Patient with presence of bone marrow involvement.
H = high-dosing regimen (15 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 75 cGy with 131I-tositumomab); H+ = increased high-dosing regimen (above 15 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 75 cGy with 131I-tositumomab); L = low-dosing regimen (11 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 65 cGy with 131I-tositumomab); L− = reduced low-dosing regimen (below 11 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 65 cGy with 131I-tositumomab).
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
- A Compartmental Model of Mouse Thrombopoiesis and Erythropoiesis to Predict Bone Marrow Toxicity After Internal Irradiation
- Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer
- Imaging a functional tumorigenic biomarker in the transformed epithelium
- Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
- Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging
- RADAR Commentary: Evolution and Current Status of Dosimetry in Nuclear Medicine